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Abstract
Background: Radiotherapy (RT) delivered in deep inspiration breath-hold (DIBH) is a simple technique, in which
changes in patient anatomy can significantly reduce the irradiation of the organs at risk (OARs) surrounding the
treatment target. DIBH is routinely used in the treatment of some adult patients to diminish the risk of late effects;
however, no formalized studies have addressed the potential benefit of DIBH in children.
Methods/Design: TEDDI is a multicenter, non-randomized, feasibility study. The study investigates the dosimetric
benefit of RT delivered in DIBH compared to free breathing (FB) in pediatric patients. Also, the study aims to
establish the compliance to DIBH and to determine the accuracy and reproducibility in a pediatric setting. Pediatric
patients (aged 5–17 years) with a tumor in the mediastinum or upper abdomen with the possible need of RT will
be included in the study. Written informed consent is obligatory. Prior to any treatment, patients will undergo a
DIBH training session followed by a diagnostic PET/CT- or CT-staging scan in both DIBH and FB. If the patient
proceeds to RT, a RT planning CT scan will be performed in both DIBH and FB and two separate treatment plans
will be calculated. The superior treatment plan, i.e. equal target coverage and lowest overall dose to the OARs, will
be chosen for treatment. Patient comfort will be assessed daily by questionnaires and by adherence to the
respiratory management procedure.
Discussion: RT in DIBH is expected to diminish irradiation of the OARs surrounding the treatment target and
thereby reduce the risk of late effects in childhood cancer survivors.
Trial registration: The Danish Ethical Committee (H-16035870, approved November 24th 2016, prospectively
registered). The Danish Data Protection Agency (2012–58-0004, approved January 1st 2017, prospectively
registered). Registered at clinicaltrials.gov (NCT03315546, October 20th 2017, retrospectively registered).
Keywords: Deep inspiration breath-hold, Pediatric patients, Radiotherapy
Background
Long-term survival following childhood cancer is ex-
cellent, with 5-year overall survival rates exceeding 80%
[1, 2]. It is, however, thoroughly documented that child-
hood cancer survivors suffer from a treatment-induced
excess mortality and morbidity when compared to the
general population or siblings [3–5].
Radiotherapy (RT) is known to induce late effects
in childhood cancer survivors; primarily cardiovas-
cular disease and second cancers [5–10]. Due to the
long latency period, radiation-induced late effects
are difficult to assess and quantify as they are often
the consequence of treatment regimens now consid-
ered outdated. Nonetheless, the risk of radiation-
induced late effects is known to be influenced by
both the radiation dose and the volume of irradi-
ated tissue [7, 11–13].
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In modern RT, advanced imaging, highly conformal
treatment planning and delivery techniques, as well as
respiratory motion management systems have been in-
troduced in the adult setting in order to reduce the radi-
ation to healthy organs at risk (OARs) surrounding the
treatment target. Deep inspiration breath-hold (DIBH) is
a simple technique where the irradiation is delivered
only while the patient holds his/her breath. A breath-
hold in deep inspiration causes a change in patient anat-
omy (i.e. inflation of the lungs, rotation and elongation
of the heart) and imaging artifacts from respiratory
movement are diminished. The technique significantly
reduces the radiation dose to the surrounding OARs,
without compromising the delivered radiation dose to
the treatment target, and with no detriment to other
healthy organs [14–17]. The OAR dose reduction is esti-
mated to reduce the risk of late effects [18]. Conse-
quently, DIBH is widely used across the world for adult
patients with left-sided breast cancer and mediastinal
lymphoma.
However, the experience with DIBH in the pediatric
setting is sparse [19, 20]. In general there has been a re-
luctance to implement new RT techniques in the
pediatric setting as late effects data are not available with
these new techniques. Regarding motion management
systems an additional concern has been the skepticism
about children’s compliance with breathing instructions.
With TEDDI we will introduce radiotherapy delivery
in deep-inspiration for pediatric patients within a multi-
center setting through the NOPHO (Nordic Society of
Pediatric Haematology and Oncology) network; accom-
modating the need for systematic research of RT delivery
techniques in pediatric patients.
Methods/Design
Aims and hypothesis
TEDDI aims to
1) Estimate the dosimetric benefit of RT using DIBH
compared to free breathing (FB) in pediatric patients.
Hypothesis 1: For more than 75% of patients,
treatment in DIBH will be dosimetrically superior to
treatment in FB.
2) Establish the compliance of DIBH in pediatric patients.
Hypothesis 2: Over 90% of pediatric patients from the
age of five years will be able to perform stable,
reproducible, and comfortable DIBHs (of 20 seconds)
through their course of RT.
3) Determine if DIBH is an accurate and reproducible
strategy for pediatric patients.
Hypothesis 3: The tumor position will be
reproducible from day to day, as well as from DIBH
to DIBH. Variations in tumor position will be less
than 5 mm over the whole treatment course.
Patients
25 consecutive, pediatric cancer patients will be included.
Inclusion criteria:
 Age 5–17 years.
 Patients with a tumor in the mediastinum or upper
abdomen with the possible need for RT according to
current treatment guidelines, irrespective of cancer
diagnosis.
 The ability to perform three sequential DIBHs of
20 s each during a training session.
 Written informed consent from parent(s) or legal
guardian(s).
Exclusion criteria
 Age < 5 years or > 17 years at time of diagnosis.
 The need for sedation during RT.
 CNS tumor or pelvic localization.
 Unable to understand DIBH coaching information
directly or through interpretation.
Patient information
Patient and parent(s) will receive written and oral infor-
mation about the protocol and be accrued prior to start
of any treatment (chemotherapy or surgery) at the
Pediatric Department.
Training session
The patient and parent(s) receive oral and written in-
struction on how to perform DIBHs. The information is
adjusted to the individual patient’s age. At Rigshospitalet
the Real-time Position Management (RPM) system from
Varian Medical Systems (Palo Alto, USA) is used to per-
form and monitor DIBHs (during training, scanning,
and treatment) [21]. The system consists of a small plas-
tic marker box which is placed on the patient’s thoracic
wall. The depth of inspiration is followed by an infra-red
camera and expressed by the anterior-posterior displace-
ment of the marker box. The patient is given visual feed-
back from a video screen which illustrates the level of
inspiration; cf. Fig 1. Non-respiratory movement is de-
tected through careful visual observation of the patient.
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The patient is deemed compliant if he/she successfully
completes three sequential DIBHs of 20 s each during
the 20 min training session.
Treatment planning
All diagnostic imaging during treatment and treatment
planning will be performed according to national guide-
lines (as per cancer diagnosis). For optimal RT planning,
the patient must be scanned upfront (pre-chemotherapy
and/or pre-surgery) in the treatment position (i.e. in the
supine position with arms raised over the head) in both
DIBH and FB. This way the uncertainties in the image
registration and fusion between the upfront imaging and
imaging for treatment planning are minimized. When-
ever a positron emission tomography (PET) scan is con-
sidered an integral part of the RT planning, a PET scan
should be performed upfront as well [22]. The additional
PET/computed tomography (CT) scan in DIBH can be
conducted as a limited one-bed PET/CT scan over the
mediastinal region, preferably in a joint session with the
staging PET/CT scan. However, for institutions where
this is not feasible, participation in TEDDI is still pos-
sible, and an upfront CT scan in both DIBH and FB will
be sufficient.
For RT planning, a planning CT scan will be per-
formed in DIBH as well as in FB for each patient.
Two RT plans will be made based on information
from both pre- and post-chemotherapy DIBH and FB
CT scans following international guidelines [23, 24]. On
both scans the gross tumor volume (GTV), the clinical
target volume (CTV), and the planning target volume
(PTV) will be delineated. The PTV margin is left at the
discretion of the treating institution and will be related
to the specific positioning and image guidance strategies
for each treatment site. All relevant OARs within the
irradiated volume will be contoured (e.g. heart, female
breasts, lungs, esophagus, thyroid, salivary glands, spinal
cord, bone marrow, stomach, spleen, kidneys, and liver).
The RT plan in DIBH and in FB will be calculated, both
with similar planning objectives for the treatment target
and OARs. All DIBH treatment plans will be designed to
keep the number of breath-holds per fraction as low as
reasonably achievable (including image guidance) for pa-
tient comfort.
Treatment delivery
Patients will be treated in DIBH if the treatment plan in
DIBH is superior to the treatment plan in FB with re-
spect to the lowest overall dose to the OARs while main-
taining acceptable target coverage. Coverage of the CTV
and PTV will have the highest priority, as per ICRU83
guidelines [25]. The prioritizing of different OARs as
well as the final choice of treatment plan will be at the
discretion of the treating radiation oncologist.
To ensure the accuracy of the treatment delivery,
image guided RT will be employed using daily volumet-
ric imaging, planar kV imaging or surface imaging, de-
pending on target location and institution.
Cf. Fig 2 for a display of estimated workflow during
accrual and treatment planning.
Follow-up
Enrollment in TEDDI will not affect the standard
follow-up program of pediatric patients, which is diag-
nosis specific.
Safety
Procedures for patient safety and quality assurance dur-
ing RT will be adhered to, irrespective of treatment in
DIBH or FB. Patient compliance will be assessed
through a questionnaire after each delivered RT fraction.
Patients that initially or at any point during treatment
cannot comply with the DIBH procedure will be treated
in FB. A change from DIBH to FB must not cause a
delay in the patient’s treatment course.
Ethical considerations
Patient consent files will be kept at the local institutions.
All data (e.g. clinical report forms, imaging, and radi-
ation treatment information) will be anonymized, and
saved for a period of ten years. All data analysis will be
performed in Copenhagen.
Patients participating in TEDDI will be exposed to an
additional radiation of approximately 5 mSv originating
from the additional staging PET/CT scan (or CT scan)
in DIBH. This corresponds to approximately 1.5 years of
exposure to the natural background irradiation. Patients
who are referred to RT will receive additional approxi-
mately 10 mSv from the additional planning CT scan in
Fig. 1 A six year old healthy volunteer perform deep inspiration
breath-hold using the Real-time Position Management system from
Varian Medical Systems (Palo Alto, USA). The screen provides a visual
feed-back and helps guide the volunteer’s respiration. Notice how
the immobilization device does not support the volunteer sufficiently;
if the volunteer was to receive radiotherapy a custom made fixation
device should be constructed
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DIBH. We expect the potential benefits of DIBH in
terms of a reduced dose to the heart and lungs and
possibly also other organs will markedly outweigh this
additional risk.
Data analysis
TEDDI is a non-randomized feasibility study and for this
mainly descriptive statistics will be applied. The patient
cohort will be described by demographic data, histo-
logical diagnosis, stage, age, and gender. For each pa-
tient, target volumes (GTV, CTV, and PTV) and OARs
volumes of the two planning CT scans will be compared.
Maximum and mean doses as well as the volumes ex-
posed to 5/10/20/30 Gy will be compared. The Wil-
coxon signed rank test for paired data will be used for
statistical testing.
The dosimetric parameters are surrogate markers for
the potential clinical benefit with DIBH compared to FB
RT plans as an observed, significant reduction in
treatment-induced late effects would require several
decades of follow-up in a patient cohort consisting of
several hundreds of patients. The expected clinical im-
plications will, however, be estimated by applying normal
tissue complication probability-models derived from
clinical case-control and cohort studies.
Patient compliance is defined as patient comfort
and DIBH reproducibility. Hence compliance will be
assessed using both qualitative and quantitative mea-
sures. Patient comfort will be assessed through daily
questionnaires based on a 5-point Likert scale. Tumor
position will be used to evaluate the ability of patients
to maintain the breath-hold during the whole course
of treatment and to investigate the possibility that
patients might get weaker and/or more tired and thus
unable to perform a stable DIBH as the treatment
course progresses. This will be done using the re-
spiratory motion management system.
The accuracy of the treatment delivery will be evalu-
ated based on daily imaging. If the target is not visible,
the sternum (mediastinal tumors) or the diaphragm (ab-
dominal tumors) will be used as a surrogate structure. If
the target position appears reproducible within 5 mm,
the patient will be deemed compliant. In addition to the
daily online positioning at the treatment machine before
each fraction, the reproducibility of the target position
will be assessed retrospectively by a medical physicist on
a weekly basis.
Fig. 2 Chart of estimated workflow during accrual and treatment planning. Abbreviations: CT = computed tomography; DIBH = deep inspiration
breath-hold; FB = free breathing; PET = positron emission tomography; RT = radiotherapy
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Sample size
Sample size is calculated based on a presumed mean
heart radiation dose of 4 Gy in FB and a 25% reduction
in mean heart dose with treatment in DIBH, with a
standard deviation of 1.5 Gy across the patient group
[16]. Recruiting 22 patients would lead to a power of 0.
85 to detect this dosimetric difference. The Type 1 error
probability is set at 0.05.
Collaborators
TEDDI is open for accrual in Denmark. However, in
order to ensure a faster accrual as well as a higher pa-
tient number to demonstrate uniformity across cancer
diagnoses participation in TEDDI is planned within the
NOPHO network in Sweden and Finland (Helsinki,
Kuopio, Oulu, Turku, and Tampere).
Discussion
The dosimetric benefit from RT in DIBH has been well
documented in the adult setting [14–17], however re-
spiratory motion management is not routinely used in
the pediatric setting.
TEDDI is the first formalized study to introduce RT
delivery in DIBH for pediatric patients.
Prior to clinical implementation of TEDDI, a pilot
study was conducted at Rigshospitalet in order to inves-
tigate whether children from the age of five are able to
perform stable and reproducible DIBHs using the RPM
system. To assess the patient compliance qualitatively,
the participating children and families completed a ques-
tionnaire after the DIBH training session. The question-
naire evaluated the child’s comfort with the pre-training
information and the DIBH coaching. Based on experi-
ences gained from this pilot study a standard operating
procedure for RT delivery in DIBH for pediatric patients
has been developed.
Two prior studies have described the experience with
DIBH in pediatric patients [19, 20]. Both studies used a
spirometry-assisted breath-hold technique. Claude et al.
[19] concluded that only older children are able to com-
ply and understand the technique, and it increases the
estimated daily treatment time at the linac. Spirometry-
assisted DIBH has in adults been reported less comfort-
able than the optical surface tracking DIBH approach
[26], employed in TEDDI. Our DIBH-method is per-
formed as a non-invasive procedure and constitutes a
very gentle treatment expected to cause a minimal in-
convenience to this fragile patient population. When
treating very young children, however, prolonged treat-
ment time at the linac might be unavoidable.
Recently Huijskens et al. investigated the respiratory-
induced motion of the diaphragm and the intra- and inter-
fractional variability in children during image-guided RT
[27]. They found a large range of the diaphragm amplitude
motion, mean 10.7 mm (range 4.1–17.4 mm), with the
intrafractional variability being the largest. Because of the
substantial patient variability they concluded that a 4DCT
in children should be performed to quantify the individual
respiratory motion in order to define individual safety
margins. TEDDI will clarify whether RT in DIBH can re-
duce this variability, potentially allowing for smaller mar-
gins and, thus, a reduced dose to the OARs.
DIBH seems to be compatible with proton therapy,
however, data and availability is still limited. The experi-
ence gained from TEDDI will be directly transferable to
proton treatment facilities. Also, DIBH holds the poten-
tial for synergistic combinations with other new RT
principles, e.g. dose painting with a boost to radio-
resistant areas of the tumor, as this technique requires
that tumor motion is minimal in order to deliver the
radiation dose correctly.
In conclusion, RT in DIBH is a promising technique in
a pediatric setting, which could have a dramatic impact
on the risk of late effects following RT for childhood
cancer, improving subsequent quality of life, morbidity,
and - ultimately - mortality.
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